|1.||Krell, Hans-Willi: 6 articles (02/2007 - 03/2002)|
|2.||Lein, Michael: 4 articles (02/2007 - 03/2002)|
|3.||Jung, Klaus: 4 articles (02/2007 - 03/2002)|
|4.||Loening, Stefan A: 3 articles (02/2007 - 02/2003)|
|5.||Abramjuk, Claudia: 2 articles (02/2007 - 09/2005)|
|6.||Rothaug, Winfried: 2 articles (02/2007 - 03/2002)|
|7.||Juchem, Rolf: 2 articles (09/2005 - 03/2002)|
|8.||Stephan, Carsten: 2 articles (09/2005 - 03/2002)|
|9.||Schnorr, Dietmar: 2 articles (02/2003 - 03/2002)|
|10.||Ortel, Bernhard: 2 articles (02/2003 - 03/2002)|
02/01/2007 - "Therapeutic efficacy of the novel matrix metalloproteinase (MMP) inhibitor Ro 28-2653 has been shown in various models of different tumor entities. "
02/01/2007 - "Ro 28-2653 reduced the tumor weight by 86%. "
06/15/2004 - "Furthermore, Ro-28-2653 reduced tumor vascularization and blocked angiogenesis in a rat aortic ring assay. "
02/15/2003 - "Animals with tumors and treated with the MMP inhibitor RO 28-2653 had both a lower tumor volume and a lower plasma MMP-9 concentration compared with controls. "
03/27/2002 - "Ro 28-2653 reproducibly reduced the tumor weights by up to 90% in a dose-dependent manner. "
|2.||Prostatic Neoplasms (Prostate Cancer)
03/27/2002 - "A novel inhibitor, Ro 28-2653, with high selectivity for MMP2, MMP9 and membrane type 1-MMP was evaluated in an orthotopic prostate cancer rat model. "
09/01/2005 - "The new MMP inhibitor Ro 28-2653 reduces tumor growth and provides a compatible therapeutic alternative for patients with prostate cancer."
06/01/2002 - "Ro 28-2653, a novel synthetic MMP inhibitor, is able to reduce tumor growth in orthotopic prostatic cancer in rats (R3327 Dunning tumor). "
02/01/2007 - "We hypothesized that the inhibitor effect of Ro 28-2653 on the tumor growth could be improved by combination with chemotherapeutic drugs and examined therefore the effect of Ro 28-2653 alone and in combination with etoposide or estramustine in the MatLyLu Dunning R-3327 rat tumor model characteristic for the androgen-independent prostate cancer (PCa). "
09/01/2005 - "Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats."
|3.||Vascular Diseases (Vascular Disease)
01/15/2008 - "Downregulation of MMPs using genetic manipulations of endogenous TIMPs, or synthetic pharmacological inhibitors such as BB-94 (Batimastat) and doxycycline, and Ro-28-2653, a more specific inhibitor of gelatinases and membrane type 1-MMP, could be beneficial in reducing the MMP-mediated vascular dysfunction and the progressive vessel wall damage associated with vascular disease."
12/01/2006 - "Thus we evaluated the influence of selective MMPI Ro 28-2653 on the incidence of liver metastases and the concentration of MMP-2 and MMP-9 in ductal pancreatic adenocarcinoma in Syrian hamster. "
06/15/2004 - "In vivo, Ro-28-2653 reduced the growth of tumors induced by the inoculation of different cell lines producing MMPs and inhibited the tumor-promoting effect of fibroblasts on breast adenocarcinoma cells. "
|4.||Etoposide (VP 16)
|6.||batimastat (BB 94)
|9.||glucuronyl glucosamine glycan sulfate (Vessel)
|2.||Induced Hyperthermia (Thermotherapy)